Starch Medical Inc (SMI), a San Jose, CA-based medical device manufacturer, announces the
introduction of its advanced PerClot™ Laparoscopic hemostat in the European Union and other
major international markets. PerClot™ Laparoscopic, a delivery configuration within the
PerClot™ Polysaccharide Hemostatic System (PHS), was awarded CE approval in 2008.
Perclot™ Laparoscopic is a hemostatic system designed for applications in minimally invasive
surgical procedures.
The PerClot™ Laparoscopic system contains a unique instrument for precise delivery of AMP™
particles through the laparoscope to the bleeding site. The delivery instrument is easily attached
to the PerClot™ bellows dispenser and enables hemostat delivery under direct vision to the
wound site for the control of capillary, venous and arterial bleeding. The PerClot™ laparoscopic
instrument can be employed in the working channel of a standard laparoscope for the delivery of
AMP™ particles.
Absorbable Modified Polymer (AMP™) technology is a sophisticated, proprietary engineering
process that modifies plant starch into ultra-hydrophilic, adhesive forming hemostatic polymers.
AMP™ materials are biocompatible, absorbable polysaccharides containing no animal or human
components.
David Lang, President of SMI, commented “The clinical introduction of PerClot™ Laparoscopic
and its proprietary, integrated AMP™ technology represents a unique advancement in hemostatic
delivery. The company is pleased to offer surgeons a delivery option which will enhance the
control of bleeding in the expanding practice of minimally invasive surgery. The performance
features of PerClot™ Laparoscopic were favorably received in pre-introduction evaluations in
Europe, Asia and Latin America. Additional clinical studies will be conducted at key medical
centers in Europe.”
PerClot™ Laparoscopic, as well as other customized, minimally invasive instruments under
development, will be displayed at the 17th International Congress of the European Association for
Endoscopic Surgery (www.eaes-eur.org) in Prague, Czech Republic in June, 2009.
SMI is a privately-held medical device company engaged in the design, manufacture, marketing
and licensing of breakthrough, hemostatic solutions. SMI’s proprietary, patent-pending
technology platform (AMP™), including powders, foams and films, will focus on the worldwide,
multi-billion dollar biomaterial, hemostasis, and wound care marketplace. For additional
information, distribution inquiries, and licensing options, please visit www.starchmedical.com.
Contact:
David Lang
Tel: 651-270-6660
Starch Medical Inc
2150 Ringwood Avenue • San Jose, CA 95131
Tel: 408-428-9818 Fax: 408-383-9189
info@starchmedical.com
www.starchmedical.com
